urea has been researched along with Alkalosis, Respiratory in 5 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Alkalosis, Respiratory: A state due to excess loss of carbon dioxide from the body. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We here describe an infant with respiratory alkalosis within the first two days of life and a high plasma level of ammonia (> 700 micromol/L)." | 1.35 | [A newborn infant with hyperventilation]. ( Bakken, M; Fugelseth, D; Lindemann, R; Myhre, MC; Rustad, CF; Woldseth, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lindemann, R | 1 |
| Myhre, MC | 1 |
| Bakken, M | 1 |
| Fugelseth, D | 1 |
| Rustad, CF | 1 |
| Woldseth, B | 1 |
| Brusilow, SW | 2 |
| Maestri, NE | 1 |
| Leitch, AG | 1 |
| Clancy, L | 1 |
| Flenley, DC | 1 |
| Campbell, AG | 1 |
| Rosenberg, LE | 1 |
| Snodgrass, PJ | 1 |
| Nuzum, CT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Crossover Study of Sodium Phenylbutyrate and Low-Dose Arginine Compared to High-Dose Arginine Alone on Liver Function, Ureagenesis and Subsequent Nitric Oxide Production in Patients With Argininosuccinic Aciduria[NCT00345605] | Phase 2 | 12 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | micromoles/L (Median) |
|---|---|
| High-dose Arginine Alone | 129 |
| Low-dose Arginine Plus Buphenyl | 53 |
(NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | micromole/l (Median) |
|---|---|
| High-dose Arginine Alone | 69 |
| Low-dose Arginine Plus Buphenyl | 53 |
The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed. This is due to the variations between different batches of manufacturer's tissue factor used in the reagent to perform the test. The INR was devised to standardize the results. Each manufacturer assigns an ISI value (International Sensitivity Index) for any tissue factor they manufacture. The ISI value indicates how a particular batch of tissue factor compares to an international reference tissue factor. The ISI is usually between 1.0 and 2.0. The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used. (NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | seconds (Mean) |
|---|---|
| Low-dose Arginine Plus Buphenyl | 14.2 |
| High Dose Arginine Alone | 13.8 |
(NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | micromoles/kg/hr (Mean) |
|---|---|
| High-dose Arginine Alone | 215 |
| Low-dose Arginine Plus Buphenyl | 97 |
Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured. (NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | IU/L (Mean) | |
|---|---|---|
| Plasma AST | ALT | |
| High Dose Arginine Alone | 52 | 57.86 |
| Low-dose Arginine Plus Buphenyl | 36.2 | 31.7 |
Plasma levels of coagulation factors I and IX were used as measures of hepatic synthetic function since the treatment duration was short. (NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | mg/dL (Mean) | |
|---|---|---|
| I | IX | |
| High Dose Arginine Alone | 229.77 | 98.36 |
| Low-dose Arginine Plus Buphenyl | 222.22 | 105.33 |
Prothrombin time (PT) and partial thromboplastin time (PTT) were measured PT measures factors I (fibrinogen), II (prothrombin), V, VII, and X, while PTT is a performance indicator of the efficacy of the common coagulation pathways. (NCT00345605)
Timeframe: Measured after each 1-week treatment period
| Intervention | seconds (Mean) | |
|---|---|---|
| PT | PTT | |
| High Dose Arginine Alone | 13.8 | 30.98 |
| Low-dose Arginine Plus Buphenyl | 14.25 | 30.91 |
2 reviews available for urea and Alkalosis, Respiratory
| Article | Year |
|---|---|
Urea cycle disorders: diagnosis, pathophysiology, and therapy.
Topics: Adolescent; Algorithms; Alkalosis, Respiratory; Amino Acid Metabolism, Inborn Errors; Ammonia; Child | 1996 |
Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy.
Topics: Adult; Alkalosis, Respiratory; Ammonia; Brain Diseases; Brain Edema; Diagnosis, Differential; Female | 1995 |
1 trial available for urea and Alkalosis, Respiratory
| Article | Year |
|---|---|
The effect of bendrofluazide and frusemide on the ventilatory response to carbon dioxide and hypoxia in normal man.
Topics: Adult; Alkalosis, Respiratory; Bendroflumethiazide; Carbon Dioxide; Chlorides; Furosemide; Humans; H | 1974 |
2 other studies available for urea and Alkalosis, Respiratory
| Article | Year |
|---|---|
[A newborn infant with hyperventilation].
Topics: Alkalosis, Respiratory; Diagnosis, Differential; Fatal Outcome; Humans; Hyperammonemia; Infant, Newb | 2008 |
Ornithine transcarbamylase deficiency: a cause of lethal neonatal hyperammonemia in males.
Topics: Alkalosis, Respiratory; Amino Acid Metabolism, Inborn Errors; Amino Acids; Ammonia; Blood Urea Nitro | 1973 |